Yahoo
NasdaqGS - Delayed Quote USD

TherapeuticsMD, Inc. (TXMD)

2.0700 0.0000 (0.00%)
At close: August 11 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for TXMD
  • Previous Close 2.0700
  • Open 2.0700
  • Bid 2.0700 x 100
  • Ask 2.1000 x 200
  • Day's Range 2.0700 - 2.1791
  • 52 Week Range 0.9900 - 2.9500
  • Volume 14,502
  • Avg. Volume 36,704
  • Market Cap (intraday) 23.959M
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) 207.00
  • EPS (TTM) 0.0100
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

www.therapeuticsmd.com

1

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More
TherapeuticsMD: Q3 Earnings Snapshot

TherapeuticsMD: Q3 Earnings Snapshot

TherapeuticsMD: Q2 Earnings Snapshot

TherapeuticsMD: Q2 Earnings Snapshot

Performance Overview

Trailing total returns as of 8/11/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TXMD
26.99%
S&P 500 (^GSPC)
12.89%

1-Year Return

TXMD
91.67%
S&P 500 (^GSPC)
21.26%

3-Year Return

TXMD
47.73%
S&P 500 (^GSPC)
73.12%

5-Year Return

TXMD
95.45%
S&P 500 (^GSPC)
73.96%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY23
Revenue 437k
Earnings -2.41M

Q3

FY22

Q4

FY22

Q1

FY23

Q2

FY23

-20M
0
20M
40M
60M

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    24.02M

  • Enterprise Value

    21.43M

  • Trailing P/E

    207.50

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.17

  • Price/Book (mrq)

    0.89

  • Enterprise Value/Revenue

    6.39

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.34%

  • Return on Assets (ttm)

    -2.95%

  • Return on Equity (ttm)

    0.32%

  • Revenue (ttm)

    3.35M

  • Net Income Avi to Common (ttm)

    86k

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.42M

  • Total Debt/Equity (mrq)

    21.62%

  • Levered Free Cash Flow (ttm)

    301.25k

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.0700 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: